1ST Source Bank held its position in Endocyte Inc. (NASDAQ:ECYT) during the second quarter, Holdings Channel reports. The firm owned 32,942 shares of the biopharmaceutical company’s stock at the end of the second quarter. 1ST Source Bank’s holdings in Endocyte were worth $106,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the company. Bellevue Group AG acquired a new stake in shares of Endocyte during the first quarter worth approximately $310,000. Cribstone Capital Management LLC boosted its stake in shares of Endocyte by 45.5% in the second quarter. Cribstone Capital Management LLC now owns 47,349 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 14,808 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Endocyte by 23.9% in the first quarter. Renaissance Technologies LLC now owns 63,400 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 12,239 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Endocyte by 2.5% in the first quarter. Geode Capital Management LLC now owns 245,677 shares of the biopharmaceutical company’s stock worth $761,000 after buying an additional 6,022 shares during the last quarter. 36.48% of the stock is currently owned by institutional investors and hedge funds.
Shares of Endocyte Inc. (NASDAQ:ECYT) traded down 1.38% on Wednesday, hitting $2.86. 174,638 shares of the stock traded hands. The stock’s market cap is $120.87 million. The company’s 50 day moving average is $3.08 and its 200 day moving average is $3.37. Endocyte Inc. has a one year low of $2.65 and a one year high of $5.63.
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Endocyte had a negative net margin of 58,957.14% and a negative return on equity of 24.71%. During the same period in the previous year, the firm earned ($0.25) EPS. On average, equities analysts forecast that Endocyte Inc. will post ($1.12) EPS for the current year.
ECYT has been the topic of several analyst reports. Zacks Investment Research cut shares of Endocyte from a “buy” rating to a “hold” rating in a research note on Tuesday. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $8.19.
Endocyte Company Profile
Want to see what other hedge funds are holding ECYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endocyte Inc. (NASDAQ:ECYT).
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.